Graphite biotech

Graphite biotech DEFAULT

Graphite Bio: gene editing blood stem cells for sickle cell disease

  • NEWS FEATURE

Ex vivo gene editing of hematopoietic stem cells using CRISPR–Cas9 and adeno-associated virus serotype 6 is ready for trials in people with sickle-cell disease.

Sickle cell disease has been a neglected area of drug development, with limited treatment options to prevent the associated debilitating pain and early mortality. With the maturation of cell and gene therapy, however, several cutting-edge treatments that have entered clinical testing aim to undo the damage caused by a mutation in the β-globin gene. Most existing gene therapy approaches supplement faulty production of β-globin with a compensating foreign gene—in the case of bluebird bio, for example, patients are given a lentiviral vector containing a T87Q-engineered form of the human β-globin gene that inserts at distant points in the genome and confers potent anti-sickling activity.

doi: https://doi.org/10.1038/d41587-021-00010-w

Related Articles

Sours: https://www.nature.com/articles/d41587-021-00010-w

Josh Lehrer, Graphite Bio CEO

June 25, 2021 09:37 AM EDTUpdated 10:41 AM

Financing

Graphite Bio leads this week's IPO squad, look­ing to turn the tide on sick­le cell dis­ease with gene edit­ing

Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.

Biotech’s IPO march continued earlier this week with Monte Rosa pricing on Thursday, and now Friday’s bunch heads to Nasdaq led by gene editing player Graphite Bio.

Located in South San Francisco, Graphite is going public Friday on the heels of a $238 million raise less than 10 months after getting started with a Series A. It’s been a rapid ascent, CEO Josh Lehrer told Endpoints News, but he feels the company is now at the point where it can focus both on drug development and further building out its platform.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 119,900+ biopharma pros reading Endpoints daily — and it's free.

SPONSORED

October 11, 2021 06:00 AM EDT

Biotech Half­time Re­port: Af­ter a bumpy year, is biotech ready to re­bound?

Brian Abrahams

Co-Head of Biotechnology Research

The biotech sector has come down firmly from the highs of February as negative sentiment takes hold. The sector had a major boost of optimism from the success of the COVID-19 vaccines, making investors keenly aware of the potential of biopharma R&D engines. But from early this year, clinical trial, regulatory and access setbacks have reminded investors of the sector’s inherent risks.

RBC Capital Markets recently surveyed investors to take the temperature of the market, a mix of specialists/generalists and long-only/ long-short investment strategies. Heading into the second half of the year, investors mostly see the sector as undervalued (49%), a large change from the first half of the year when only 20% rated it as undervalued. Around 41% of investors now believe that biotech will underperform the S&P500 in the second half of 2021. Despite that view, 54% plan to maintain their position in the market and 41% still plan to increase their holdings.

October 17, 2021 05:42 PM EDTUpdated 7 hours ago

R&D

Bio­gen hit by ALS set­back with PhI­II fail­ure for tofersen — but fol­lows a fa­mil­iar strat­e­gy high­light­ing the pos­i­tive

John Carroll

Editor & Founder

Patients and analysts waiting to hear Sunday how Biogen’s SOD1-ALS drug tofersen fared in Phase III didn’t have to wait long for the top-line result they were all waiting for. The drug failed the primary endpoint on significantly improving the functional and neurologic decline of patients over 28 weeks as well as the extension period for continued observation.

In fact, there was very little difference in response.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 119,900+ biopharma pros reading Endpoints daily — and it's free.

Jeffrey Nau, Oyster Point Pharma CEO

FDA OKs an in­haled ver­sion of smok­ing ces­sa­tion drug Chan­tix — for a com­mon eye dis­ease

Paul Schloesser

Editorial Intern

Oyster Point Pharma now has its first FDA-approved product — Tyrvaya. And the biotech has taken a unique route to get there by using an old drug with a storied past.

The New Jersey biotech announced this morning that the FDA has approved their nasal spray product for dry eye disease on Friday — the first nasal spray to be approved for the disease. The product’s active ingredient is 0.03 mg of varenicline, also known as smoking cessation aid Chantix.

Langer, Ciechanover god­fa­ther the lat­est AI up­start; Ipsen forges $446M AML de­vel­op­ment pact

John Carroll

Editor & Founder

There’s a new AI player jumping into the drug discovery game. And they have some high-powered scientific advisors in their corner.

Tel Aviv-based Quris has built what it calls a “patient-on-a-chip” AI platform that it’s touting as a way to circumvent unreliable animal testing with a more efficient way to judge safety and efficacy. Animal testing, particularly involving mice, has proven a notoriously unreliable way to do preclinical testing — though it is well-established with regulators.

Sheldon Koenig, Esperion CEO

Es­pe­ri­on gets out the bud­get ax, chop­ping 170 staffers as its big drug launch sput­ters

Esperion’s executive team spent years insisting that they had found the sweet spot in the market for their cholesterol drug. But that strategy has soured badly, and after struggling to sell its heart disease pill for more than a year, the biotech says it will cut about 40% of its staff over the next few weeks.

The layoffs will take place across the board, from sales and marketing to R&D, CEO Sheldon Koenig told Endpoints News on Monday. While the chief executive declined to elaborate on how many employees will be affected, an SEC filing stated that approximately 170 staffers are on the chopping block.

October 18, 2021 10:35 AM EDT

FDA+

Omeros plunges deep­er af­ter FDA re­jects rare dis­ease drug, ask­ing for more in­for­ma­tion

Omeros practically warned investors that a complete response letter was coming when it disclosed that the FDA found deficiencies in its BLA for narsoplimab. But the agency did not elaborate on the specifics of those deficiencies for the drug, which was being positioned as a treatment for the rare but serious blood clotting disease known as hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).

Two drug­mak­ers hit with PDU­FA date de­lays from FDA amid back­log of in­spec­tions

Josh Sullivan

Associate Editor

As the FDA is weighed down with more and more pandemic responsibilities, the agency is beginning to miss PDUFA dates with more frequency too. Two different companies on Monday said they received notices that the FDA has not completed their drug reviews on time.

The review of an NDA for Avadel Pharmaceuticals’ candidate treatment for narcolepsy is not coming this month, the company said, and the review of UCB’s BLA for bimekizumab, used to treat moderate to severe plaque psoriasis, will miss its target date as well.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 119,900+ biopharma pros reading Endpoints daily — and it's free.

Reshma Kewalramani, Vertex CEO (YouTube)

Ver­tex gets much-need­ed win with ‘ex­tra­or­di­nary’ first pa­tient re­sults on po­ten­tial di­a­betes cure

Vertex said Monday that the first patient dosed with its cell therapy for type 1 diabetes saw their need for insulin injections vanish almost entirely, a key early step in the decades-long effort to develop a curative treatment for the chronic disease.

The patient, who had suffered five potentially life-threatening hypoglycemic — or low blood sugar — episodes in the year before the therapy, was injected with synthetic insulin-producing cells. After 90 days, the patient’s new cells produced insulin steadily and ramped up their insulin production after a meal like normal cells do, as measured by a standard biomarker for insulin production.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 119,900+ biopharma pros reading Endpoints daily — and it's free.

Boehringer nabs FDA's first in­ter­change­abil­i­ty des­ig­na­tion for its Hu­mi­ra com­peti­tor — but will it mat­ter?

Zachary Brennan

Senior Editor

The FDA late Friday awarded Boehringer Ingelheim the first interchangeability designation for its Humira biosimilar Cyltezo, meaning that when it launches in July 2023, pharmacists will be able to automatically substitute the Boehringer’s version for AbbVie’s mega-blockbuster without a doctor’s input.

The designation will likely give Boehringer, which first won approval for Cyltezo in 2017, the leg up on a crowded field of Humira competitors.

Sours: https://endpts.com/graphite-bio-leads-this-weeks-ipo-squad-looking-to-turn-the-tide-on-sickle-cell-disease-with-gene-editing/
  1. Buggy springs
  2. Worksaver parts
  3. Size 10w heels
  4. Hspt time breakdown
  5. Syllables quiz

Pharmaceuticals, Biotech & Life Sciences

Overview

Graphite consultants include some of the world’s leading experts in the pharmaceutical, biotech and life sciences industries. Calling upon their extensive and proven industry experience, they provide insights and services to guide investment, growth, organizational design, cost management and innovation in a rapidly evolving marketplace.

Our experts deliver practical solutions that help companies and investors navigate the challenges and uncertainties of doing business as well as capitalize on emerging opportunities to drive profit and create value.

Expert Capabilities

Growth Strategies

Organizational Transformation

Market Research

Data Science and Analytics

Business Development

M&A and Transaction Support

Sales and Marketing

Finance and Accounting

IT and Digital Advanced

Interim Leadership and Support

Human Resources

Private Equity and Venture Capital

Danaher, a global conglomerate and Fortune 500 life sciences company, needed an expert to augment its analytics team. It needed someone with a background in strategy, consulting, banking and qualitative marketing who could consolidate and synthesize large, complex data sets concerning market potential, revenue and channel coverage models.

Through Graphite, Danaher hired Nevin R., a Harvard graduate with Big Three management consulting experience and a private equity background. Nevin was able to deliver precisely the analysis Danaher needed while committing to the project full-time and producing high-quality insights the company used to great success.

Juno Therapeutics, a fast-growing biopharma company recently acquired by Celgene, needed financial modeling support to help with its internal valuation model. Juno needed an outside expert with investment banking and biotech experience to review and optimize the model and provide scenario analysis and sensitivities.

Juno found an ideal resource by connecting with Brian P., a former investment banking analyst, private equity associate and VP of Finance and Operations at a venture-backed SaaS firm. Brian spent time modeling numerous transactions in the biotech and biopharma space, stepping in and filling Juno’s needs within days.

Genus plc, a British publicly traded producer of bovine genetics products, needed help developing an operational strategy implementation plan. To ensure success, Genus was looking for an experienced strategy consultant that could translate a strategy vision into an operational plan that included milestones, deliverables, an implementation structure, and buy-in from the broader organization.

Through Graphite, Genus was quickly introduced to Helen Q., an innovation and strategy consultant with prior experience at McKinsey. With a strong background and experience in innovation across the corporate world, Helen proved to be the ideal candidate and helped Genus organize and implement a high-level strategy that transformed the organization.

See More Case Studies

Why Graphite

Graphite connects you with highly vetted independent consultants for on-demand work. We offer access to over 7,500 experts with an average of 12 to 15 years of experience, including over 1,600 with an MBA from a top 10 U.S. business school and many with years of experience from Bain, BCG and McKinsey.

How Graphite Works

Hiring a pre-vetted and highly qualified pharmaceutical, biotech and life sciences consultant is easy with Graphite.

Scope Your Project

Tell us what you need done and work with our account managers to finalize a scope of work, budget and timeline for your project.

Interview Candidates

Within hours, we will deliver curated candidates that match your need. Interview and select the best fit.

Get Work Done

Seamlessly launch the project on Graphite and get amazing results. Let us handle the contracting and billing.

Get Started

Ready to Hire an Industry Expert?Get Started

Looking for Experts in a different industry?

See All Industries We Serve
Sours: https://www.graphite.com/industries/pharma-biotech-life-sciences
Introduction to Graphite Bio

Graphite Bio Launches with $45 Million Series A Financing

Next-generation gene editing company launched by Versant Ventures with additional backing by Samsara BioCapital

Core technology from Stanford founders Matt Porteus and Maria Grazia Roncarolo

Josh Lehrer joins as CEO

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio today announced a $45 million Series A financing led by founding investor Versant Ventures, together with Samsara BioCapital. Graphite Bio is a next-generation gene editing company focused on targeted DNA integration to precisely insert genetic payloads to treat a variety of severe diseases. The company was co-founded by pioneers in the fields of gene editing and gene therapy and has a rapidly maturing pipeline with an upcoming IND and several other candidates advancing toward the clinic in the next 12-18 months.

While many existing gene editing and gene therapy approaches are based on knocking out or randomly integrating genes, Graphite Bio is focused on correcting defective genes by high-efficiency site-specific integration of new genetic sequences. This technology has the potential to precisely repair a damaged portion of a gene, completely replace a malfunctioning gene while retaining normal regulatory control, or to insert a wide range of therapeutic genetic cargoes into precise regions of the genome.

In addition, Graphite Bio’s technology has the potential to provide for durable expression while minimizing toxicity from off-target insertions.

“Our flexible, site-specific approach is extremely powerful and could be used to definitively correct the underlying causes of many severe genetic diseases, and also is applicable to broader disease areas,” said Josh Lehrer, M.D., CEO of Graphite Bio. “With backing from Versant and Samsara, we look forward to progressing our novel medicines into the clinic for patients with high unmet needs.”

Dr. Lehrer joined Graphite Bio after six years at Global Blood Therapeutics (NASDAQ:GBT), where he most recently served as chief medical officer. At GBT, he played a key role in the clinical development and 2019 approval of the company’s Oxbryta therapy for sickle cell disease.

A next-generation gene editing platform

CRISPR-Cas9 gene editing has transformed the biotechnology landscape due to its ability to specifically induce double-stranded DNA breaks that can disrupt genes or genetic control regions, leading to novel treatment approaches for a range of diseases. However, it has been challenging to harness CRISPR-Cas9 for the high-efficiency insertion of new genetic cargo.

Graphite Bio’s gene editing platform includes several complementary technologies that enable targeted and permanent DNA integration at very high efficiency. The platform builds on seminal work led by Dr. Danny Dever in the laboratory of Dr. Matt Porteus at Stanford University demonstrating an increase in integration efficiency from less than 1% to greater than 50% across diverse genetic lesions in a wide range of cell types.

“Achieving high-efficiency targeted gene integration has been a critical objective of gene editing for more than 15 years, but only now is this technologically possible,” said Jerel Davis, Ph.D., Managing Director at Versant and a Graphite Bio board member. “As the founding investor of CRISPR Therapeutics, Versant has seen first-hand the rapid evolution of the gene editing field. Our collaboration with Matt Porteus on CRISPR Therapeutics was highly productive. We are thrilled to be working with him on Graphite Bio, alongside Maria Grazia, Josh and Danny.”

The efficiency improvements enable clinically meaningful levels of targeted integration for therapeutic applications. The company’s medicines therefore can replace defective genes, insert genetic cargo into specific loci and significantly limit undesirable, indiscriminate transgene expression.

Graphite Bio founders and operating plans

The company’s scientific founders include:

Matthew Porteus, M.D., Ph.D., Professor of Pediatrics and Stem Cell Transplantation and the Associate Director of Center for Definitive and Curative Medicine at Stanford University. Dr. Porteus is a pioneer in the gene editing field and has been involved in the space for more than 20 years. He is an academic founder of CRISPR Therapeutics, and advisor to a number of companies in the field as well as the FDA. He has advanced several of Graphite Bio’s technologies and programs at his Stanford lab. As a pediatric hematologist, Dr. Porteus treats patients with severe genetic diseases.
Maria Grazia Roncarolo, M.D., Ph.D., Professor in Stem Cell and Regenerative Medicine, Professor of Pediatrics and of Medicine, Director of the Center for Definitive and Curative Medicine, and Co-Director of the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University. She is a global leader and pioneer in gene therapy, having served as the director of the Telethon Institute for Cell and Gene Therapy at the San Raffaele Scientific Institute in Milan. There, she advanced multiple gene therapy products into the clinic. This work ultimately led to the first approved gene therapy, Strimvelis.
Based on progress to date, Graphite Bio expects to commence Phase 1 studies of its first development candidate in early 2021. The company’s lead program specifically corrects the single nucleotide point mutation in the sickle β globin gene. In cells from patients with the disease, Graphite Bio has shown that its gene correction approach efficiently restores healthy hemoglobin protein and eliminates sickle cell hemoglobin.

In addition, Graphite Bio is advancing several other programs to the clinic, each with the potential to lead to a cure for serious unmet needs.

“It is gratifying to see our work on new gene editing approaches being translated into novel therapies,” said Dr. Porteus. “I’m very excited to be working with Versant again on a start-up and I look forward to collaborating with Samsara and the Graphite Bio team to bring a new generation of genetic treatments to patients.”

In connection with the financing, Abe Bassan, Vice President at Samsara BioCapital, and Carlo Rizzuto, Ph.D., Partner at Versant, joined Graphite Bio’s board.

About Graphite Bio

Graphite Bio is a next-generation gene editing company focused on targeted DNA integration to precisely insert genetic payloads to treat a broad range of severe diseases. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, and is backed by Versant Ventures and Samsara BioCapital. For more information, please visit www.graphitebio.com.

About Versant Ventures

Versant Ventures is a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm’s emphasis is on biotechnology companies that are discovering and developing novel therapeutics. With $3.2 billion under management and offices in the U.S., Canada and Europe, Versant has built a team with deep investment, operating and R&D expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 75 Versant companies have achieved successful acquisitions or IPOs. Versant is currently investing out of its seventh fund, Versant Venture Capital VII, a $600 million global biotech fund closed in December 2018. In parallel the firm co-invests out of its Canadian strategic fund Versant Voyageurs I and its later-stage biotech opportunity fund Versant Vantage I. For more information, please visit www.versantventures.com.

About Samsara BioCapital

Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Founded in 2016 by Srinivas Akkaraju, MD, PhD, our team of scientists, investors, and entrepreneurs takes a long-term view to value creation across all stages of public and private life science companies. We believe in a collaborative, hands-on approach, working closely with entrepreneurs to harness exciting scientific advances and build leading companies. Samsara actively manages approximately US$410 million in assets on behalf of endowments, foundations, and family offices. For more information, visit www.samsaracap.com.

Contacts
Katherine Vega Stultz, COO
[email protected]

Sours: https://otl.stanford.edu/news/graphite-bio-launches-45-million-series-financing

Biotech graphite

The girl whispered some kind of pleading with her lips, asking for protection from Cyril. But he only threatened the bandits, not even trying to free himself, in principle, he did not care about his wife's suffering, he did not love her, but these freaks were. Going to fuck his woman, humiliate him, and this aroused rage and despair in the man's soul.

Here the pumped-up guy spat on his hand, and a second later an elastic penis entered Tamara's pussy. The belly pressed closer to the hood, and the girl arched her back to protect him from the weight of the piled man.

Intro to Graphite Bio Part 2

Son, insert your dick into your mom's pussy. The guy climbed onto the bed and lay down on top of Catherine in a missionary position. She bent over and helped her son insert his dick into his hot bosom. A member dived into the cave, and she gasped. Ooooh, Mishenka !!.

You will also like:

Guttural moans, heavy breathing and reciprocal innocent touches to his own body. The young man crumples wrinkled sheets with thin fingers, slightly damp with sweat, spreads his slender legs wider and throws his head back, completely open and completely embarrassed.

Miller thinks that Grant can be stretched forever, he is so sensual. And if it were not for the incredibly painful excitement, then the man relished this moment for a long time, would. Bring the youngster to the very brink and step back, opening the whole world to him.



711 712 713 714 715